Lupin gets FDA approval for Diazepam Injection, USP
It is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Lupin
Lupin receives tentative FDA approval for enzalutamide tablets
Lupin Limited has received tentative FDA approval for Enzalutamide Tablets in four strengths, including two additional dosing options beyond the traditionally available Xtandi tablet strengths.
Lupin launches generic Azilsartan Medoxomil tablets in U.S.
Lupin has launched Azilsartan Medoxomil Tablets, the generic version of Edarbi, for the treatment of hypertension and will receive 180 days of market exclusivity as the first-to-file applicant.
Lupin and Natco get FDA approval for Eribulin Mesylate Injection
The U.S. FDA has approved Lupin and Natco’s generic version of Halaven Injection, a cancer therapy with annual U.S. sales of approximately $43.7 million.
Lupin gets U.S. FDA approval for Glycerol Phenylbutyrate Oral Liquid
Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, is bioequivalent to the reference listed drug (RLD), Ravicti® Oral Liquid, 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC.
Lupin launches Dapagliflozin tablets in the United States
The tablets are bioequivalent to Farxiga®.
Lupin CEO Vinita Gupta named to 2026 CNBC Changemakers List
The annual CNBC Changemakers list honors women whose leadership is delivering measurable business impact and long-term change.
Lupin launches first PrecisionSphere long-acting injectable in the U.S.
This technology allows for easier injection with smaller needles and more consistent drug concentrations.
Lupin announces strategic partnership program to expand reach of its long-acting injectable platform
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles.
Lupin to build $250 million manufacturing facility in Florida
The facility will produce vital respiratory medicines and bolster the company’s role as a global respiratory leader.
Lupin launches ipratropium bromide nasal solution
Ipratropium bromide nasal solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals.